Nanodrugs based on co-delivery strategies to combat cisplatin resistance

Qiubo Wang; Hui Li; Taixia Wu; Bing Yu; Hailin Cong; Youqing Shen

doi:10.1016/j.jconrel.2024.04.020

Nanodrugs based on co-delivery strategies to combat cisplatin resistance

J Control Release. 2024 Apr 16:370:14-42. doi: 10.1016/j.jconrel.2024.04.020. Online ahead of print.

Authors

Qiubo Wang¹, Hui Li¹, Taixia Wu¹, Bing Yu², Hailin Cong³, Youqing Shen⁴

Affiliations

¹ College of Chemistry and Chemical Engineering, College of Materials Science and Engineering, Institute of Biomedical Materials and Engineering, Qingdao University, Qingdao 266071, China.
² College of Chemistry and Chemical Engineering, College of Materials Science and Engineering, Institute of Biomedical Materials and Engineering, Qingdao University, Qingdao 266071, China; State Key Laboratory of Bio-Fibers and Eco-Textiles, Qingdao University, Qingdao 266071, China. Electronic address: yubing198@qdu.edu.cn.
³ College of Chemistry and Chemical Engineering, College of Materials Science and Engineering, Institute of Biomedical Materials and Engineering, Qingdao University, Qingdao 266071, China; State Key Laboratory of Bio-Fibers and Eco-Textiles, Qingdao University, Qingdao 266071, China; School of Materials Science and Engineering, Shandong University of Technology, Zibo 255000, China. Electronic address: conghailin@sdut.edu.cn.
⁴ College of Chemistry and Chemical Engineering, College of Materials Science and Engineering, Institute of Biomedical Materials and Engineering, Qingdao University, Qingdao 266071, China; Key Laboratory of Biomass Chemical Engineering of Ministry of Education, Center for Bio-nanoengineering, and Department of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang 310027, China.

PMID: 38615892
DOI: 10.1016/j.jconrel.2024.04.020

Abstract

Cisplatin (CDDP), as a broad-spectrum anticancer drug, is able to bind to DNA and inhibit cell division. Despite the widespread use of cisplatin since its discovery, cisplatin resistance developed during prolonged chemotherapy, similar to other small molecule chemotherapeutic agents, severely limits its clinical application. Cisplatin resistance in cancer cells is mainly caused by three reasons: DNA repair, decreased cisplatin uptake/increased efflux, and cisplatin inactivation. In earlier combination therapies, the emergence of multidrug resistance (MDR) in cancer cells prevented the achievement of the desired therapeutic effect even with the accurate combination of two chemotherapeutic drugs. Therefore, combination therapy using nanocarriers for co-delivery of drugs is considered to be ideal for alleviating cisplatin resistance and reducing cisplatin-related toxicity in cancer cells. This article provides an overview of the design of cisplatin nano-drugs used to combat cancer cell resistance, elucidates the mechanisms of action of cisplatin and the pathways through which cancer cells develop resistance, and finally discusses the design of drugs and related carriers that can synergistically reduce cancer resistance when combined with cisplatin.

Keywords: Cancer treatment; Cisplatin; Co-delivery; DNA; MDR; Mechanisms; Nanoparticles; Platinum complexes; Resistant.

Publication types

Review